Axe Compute

Axe Compute EBIT Growth

The Year-over-Year EBIT Growth of Axe Compute (AGPU) as of Nov 5, 2026 is -159.84 %. In the previous year, Year-over-Year EBIT Growth was 9.72 % — a change of -1,743.86% (lower).

EBIT Growth

-159.84 %

YoY

-1,743.86%

Last updated:

Year-over-Year EBIT Growth of Axe Compute is 2025 -159.84 % . Year-over-Year EBIT Growth of Axe Compute was 2024 9.72 % . It decreases by -1,743.86% lower compared to the previous year.

The Axe Compute EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2018
-29.86 USD
Jan 1, 2019
-188.05 USD
Jan 1, 2020
-11.99 USD
Jan 1, 2021
19.45 USD
Jan 1, 2022
-27.44 USD
Jan 1, 2023
53.45 USD
Jan 1, 2024
9.72 USD
Jan 1, 2025
-159.84 USD
The Axe Compute EBIT Growth history
YEAREBIT GrowthYoY
-159.84 %-1,743.86%
9.72 %-81.81%
53.45 %-294.82%
-27.44 %-241.10%
19.45 %-262.17%
-11.99 %-93.62%
-188.05 %+529.68%
-29.86 %-512.49%
7.24 %-114.98%
-48.33 %-251.16%
31.97 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Axe Compute Stock analysis

What does Axe Compute do? Predictive Oncology, Inc. generates revenue through its subsidiaries Helomics Holding Corporation and Skyline Medical Inc. Helomics applies artificial intelligence to patient tumor data to personalize cancer therapies and develop new-targeted therapies, offering CLIA-certified clinical testing for oncologists. Skyline Medical Inc. markets the STREAMWAY System, which automates medical fluid disposal, targeting hospitals and clinics globally. The company's products serve healthcare providers seeking advanced diagnostic and waste management solutions. Helomics focuses on personalized cancer treatment decisions using AI-driven analysis, while Skyline Medical Inc. provides automated fluid disposal systems. The STREAMWAY System is sold through domestic and international divisions to medical facilities requiring efficient waste handling. TumorGenesis Inc. supports laboratory-based tumor research, complementing Helomics' clinical offerings. The company's revenue streams include AI-based therapy personalization services and the STREAMWAY System sales. Healthcare providers, including oncologists and medical facilities, purchase these products to enhance treatment precision and operational efficiency. Subsidiaries operate under the parent company's structure, with Helomics handling AI applications and Skyline Medical managing medical device distribution. Axe Compute is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Axe Compute stock

Year-over-Year EBIT Growth of Axe Compute is -159.84 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Axe Compute since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Axe Compute historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Axe Compute

All Key Metrics — Axe Compute